Fampyra

E28893

Fampyra is a prescription medication (prolonged-release fampridine) used to improve walking in adults with multiple sclerosis.

AI illustration

How this image was made

AI-generated illustration of Fampyra

This AI-generated illustration was produced by black-forest-labs/FLUX.2-dev (1024x1024) from a prompt written by openai/gpt-oss-120b from the entity's label + description.

Prompt

Generate an image of a fampyra (Fampyra is a prescription medication (prolonged-release fampridine) used to improve walking in adults with multiple sclerosis.)

All labels observed (1)

Label Occurrences
Fampyra canonical 3

How this entity was disambiguated

Statements (45)

Predicate Object
instanceOf brand name drug ⓘ
medicinal product ⓘ
actsOn central nervous system ⓘ
approvalYear 2011 ⓘ
approvedBy European Medicines Agency ⓘ
commonAdverseEffect dizziness ⓘ
headache ⓘ
insomnia ⓘ
nausea ⓘ
urinary tract infection ⓘ
containsExcipient lactose ⓘ
contraindicatedIn history of seizures ⓘ
moderate or severe renal impairment ⓘ
developedBy Biogen Idec ⓘ
linked to: Biogen
dosingInterval every 12 hours ⓘ
hasActiveIngredient 4-aminopyridine ⓘ
fampridine ⓘ
hasApprovalRegion European Union ⓘ
hasATCCode N07XX07 ⓘ
hasDosageForm prolonged-release tablet ⓘ
hasInternationalNonproprietaryName fampridine ⓘ
hasRouteOfAdministration oral ⓘ
hasStrength 10 mg prolonged-release tablet ⓘ
hasTradeName Fampyra ⓘ
improvementAssessmentTool Timed 25-Foot Walk test ⓘ
improves walking ability in multiple sclerosis patients ⓘ
walking speed in multiple sclerosis patients ⓘ
indicatedFor impaired walking in multiple sclerosis ⓘ
multiple sclerosis ⓘ
intendedPopulation adults ⓘ
isExtendedReleaseFormulationOf fampridine ⓘ
legalStatusEU prescription only medicine ⓘ
marketingAuthorisationHolder Biogen Netherlands B.V. ⓘ
linked to: Biogen
mechanismOfAction blocks voltage-gated potassium channels ⓘ
enhances conduction in demyelinated axons ⓘ
notIndicatedFor patients under 18 years of age ⓘ
pharmacologicalClass potassium channel blocker ⓘ
pregnancyCategory use only if potential benefit justifies potential risk ⓘ
requires prescription ⓘ
requiresMonitoring renal function ⓘ
seizure risk ⓘ
riskManagementPlanRequiredBy European Medicines Agency ⓘ
seriousAdverseEffect seizure ⓘ
storageCondition store below 25°C ⓘ
therapeuticArea neurology ⓘ

How these facts were elicited

Referenced by (3)

Full triples — surface form annotated when it differs from this entity's canonical label.

Biogen → hasProduct → Fampyra ⓘ
Fampyra → hasTradeName → Fampyra ⓘ
fampridine → hasBrandName → Fampyra ⓘ